USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/34403
Title: HEPATITIS B REACTIVATION AFTER TENOFOVIR DISCONTINUATION IN LYME DISEASE
Authors: Nazreen, Lakshmi Dileepkhan Alka
Olaru-Stăvilă, Cătălina
Keywords: Lyme disease;Hepatitis B reactivation;immunosuppressive therapy
Issue Date: 2026
Publisher: Centrul Editorial-Poligrafic Medicina
Citation: Nazreen, Lakshmi Dileepkhan Alka; Olaru-Stăvilă, Cătălina. HEPATITIS B REACTIVATION AFTER TENOFOVIR DISCONTINUATION IN LYME DISEASE. In: MedEspera 2026, p. 588. ISBN 978-9975-82-486-6.
Abstract: Introduction. Hepatitis B virus (HBV) reactivation is considered a complication in patients with chronic hepatitis B infection, especially when the antiviral treatment is discontinued or during immunosuppression therapy. We report a case of chronic HBV reactivation due to sudden cessation of Tenofovir and corticosteroid therapy during Lyme disease evolution in a patient who had sustained HBV for more than one year. Case presentation. A 44-year-old male was admitted to the hospital with prolonged fever, fatigue, dark urine, and severe joint pain with swelling of the right shoulder and knee joints. Two months earlier he was diagnosed with a late disseminated stage of Lyme disease manifested by arthritis, myocarditis and neuroborreliosis, treated with high doses of corticosteroids, as antibiotic therapy proved to be ineffective. The patient also had a history of chronic hepatitis B infection that remained virologically suppressed for more than one year under treatment with Nucleoside analogue therapy. However, during Lyme disease treatment with corticosteroids and multiple intensive care admissions, the antiviral therapy was interrupted. Laboratory investigations revealed a severe cytolytic and inflammatory syndrome with mild cholestasis, characterized by markedly elevated transaminases (ALT 1500 U/L, AST 684 U/L), increased inflammatory markers (CRP 32 mg/L, ESR 36 mm/h), and mild hyperbilirubinemia (total bilirubin 2 mg/dL, direct bilirubin 1.4 mg/dL). Further serological tests, hepatitis A, C and D, autoimmune markers and bacterial infection were negative. Following this HBV DNA testing revealed significantly elevated viral levels (6,464,285 IU/mL). Treatment with nucleoside analogue therapy was initiated immediately resulting in near-complete normalization of transaminase level at the time of discharge. Discussions. A sudden discontinuation of Nucleoside analogue therapy without monitoring can cause significant relapse of chronic hepatitis B. Simultaneously, corticosteroid treatment is also a significant risk factor for HBV reactivation because of its immunosuppressive effects. Conclusions. The case highlights that constant antiviral therapy and close supervision among chronic hepatitis B patients who are receiving immunosuppressive therapy is important to avoid activation of HBV.
metadata.dc.relation.ispartof: MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026
URI: https://medespera.md/documents/abstract-book-4.pdf
https://repository.usmf.md/handle/20.500.12710/34403
ISBN: 978-9975-82-486-6
Appears in Collections:MedEspera 2026

Files in This Item:
File Description SizeFormat 
M-588.pdf465.94 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback